PDC expression of KRASG12V was confirmed by next-generation sequencing (NGS) (Supplemental Table 6) and Western blot analysis (Supplemental Figure 10A), and oncogene profiling with TP53, SMAD4, and CDKN2A mutations was consistent with PAAD characteristics. Here, CDKN2A is linked to pancreatic adenocarcinoma.